PRRT2 and neoplasm: In TNBC brain metastases and immunotherapy‐resistant metastatic melanoma, PKCθ activates transcriptional programs related to EMT, promotes the generation and maintenance of CSCs with a mesenchymal‐like phenotype, and thereby assists tumor cells in evading immune surveillance [255].